A 40‑Minute Test Could Turn the Tide Against Rocky Mountain Spotted Fever

When a hiker in the Ozarks feels a bite and a sudden fever, doctors often have to guess whether Rocky Mountain spotted fever is the culprit. The disease, caused by the bacterium Rickettsia rickettsii, can turn deadly in a matter of days if the right antibiotic – doxycycline – isn’t given quickly. Now, a team at the University of Missouri thinks they may have shortened that scary waiting period to less than an hour.

The breakthrough was described in a paper published this summer in Frontiers in Microbiology (DOI: 10.3389/fmicb.2026.1823193). Led by Curators’ Distinguished Professor Roman Ganta from the College of Veterinary Medicine, the researchers paired a simple isothermal amplification method called recombinase polymerase amplification (RPA) with the gene‑editing powerhouse CRISPR/Cas12a. The result? A color‑change readout that flashes a positive signal in roughly 40 minutes – two brief 20‑minute steps, all at room temperature.

"We wanted something that works outside a high‑tech lab," Ganta explained in the university’s press release. "The assay needs only a basic heat block and a cheap visual detector – no cycler, no sequencing, no high‑end fluorescence reader." That simplicity could be a game‑changer for small clinics, veterinary offices, and even field teams battling an outbreak in rural Appalachia.

Traditional diagnostics for spotted fever rely on serology, which only turns positive after the body has mounted an immune response, or on PCR, which demands expensive equipment and trained technicians. Both approaches can delay definitive treatment, and each day of postponement hikes the mortality risk, especially in children. The new test, by contrast, detects the bacterial DNA directly from a tick or a patient’s blood sample, delivering a result while the patient is still in the exam room.

In the study, the RPA‑CRISPR assay correctly identified all 25 spiked samples containing R. rickettsii, and it showed no cross‑reactivity with related rickettsial species. The limit of detection was about 10 genome copies per reaction – comparable to the best laboratory PCRs, but achieved with far less hardware.

Beyond the bench, the team is already eyeing real‑world deployment. The Veterinary Medical Diagnostic Laboratory at Mizzou has begun pilot testing on actual tick specimens collected from Missouri forests. If those trials hold up, the assay could be rolled out to partner health departments across the Midwest, where tick season stretches from April through October.

It’s worth noting that the findings have undergone peer review – the Frontiers paper passed the journal’s standard evaluation – but the technology is still in the validation phase. The researchers acknowledge that larger field studies are needed to confirm performance across diverse patient groups and environmental conditions.

Still, the prospect of a cheap, rapid, and accurate test is generating buzz. "Every hour you shave off the diagnostic window could save a life," said Ganta. "And that’s exactly why we built this thing the way we did – to be usable wherever the disease shows up, not just in a university lab."

Until the assay becomes widely available, clinicians will continue to start doxycycline empirically when spotted fever is suspected – a practice that remains the best defense. But with a 40‑minute answer on the horizon, the future of tick‑borne disease detection looks a lot less uncertain.